Current attempts to implement siRNA-based RNAi in leukemia models

•Application of RNAi technology as a therapeutic strategy for leukemia treatment.•Critical considerations in nonviral delivery of RNAi reagents.•Recent advances on molecular targets and functional RNAi delivery systems. Leukemias arise from genetic alterations in normal hematopoietic stem or progeni...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drug discovery today 2016-09, Vol.21 (9), p.1412-1420
Hauptverfasser: Uludağ, Hasan, Landry, Breanne, Valencia-Serna, Juliana, Remant-Bahadur, K.C., Meneksedağ-Erol, Deniz
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Application of RNAi technology as a therapeutic strategy for leukemia treatment.•Critical considerations in nonviral delivery of RNAi reagents.•Recent advances on molecular targets and functional RNAi delivery systems. Leukemias arise from genetic alterations in normal hematopoietic stem or progenitor cells, leading to abnormal blood population with transformed cells. With the advent of RNAi and its pharmacological mediator siRNA, it has become possible to downregulate specific drivers causing leukemias. In this review, we present unique aspects of RNAi-mediated therapy and delivery technologies. Recent updates on molecular targets and delivery systems are discussed emanating from in vitro cell models and preclinical animal models. We conclude with a view on the future of RNAi in leukemia therapy, emphasizing possible measures to achieve higher efficacy and improved safety.
ISSN:1359-6446
1878-5832
DOI:10.1016/j.drudis.2016.04.018